Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy versus observation in patients (pts) with aggressive CD20+ B-cell lymphoma and mantle cell lymphoma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Heidelberg
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• aggressive B-cell lymphoma or mantle cell lymphoma

• CR (complete remission) oder CRu (complete remission unconfirmed) after previous therapy

• PR (partial remission) only when PET is negative

• minimal age 18 years

• CD20+ expression on tumor cells

• effective contraception

• Karnofsky status > 60

• written informed consent